Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRD-based Regimen Combined With CART-ASCT-CART2 in Primary Plasma Cell Leukemia
NCT05870917Phase 2Active, not recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2023
- Primary completion
- Sep 2025
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of anti-BCMA CAR-T in plasma cell leukemia (PCL), sponsored by Institute of Hematology and Blood Diseases Hospital. Started May 2023; status: active, not recruiting.
02
Drugs
anti-BCMA CAR-T
03
Conditions
plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT05870917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05870917.